Company Profile

Avid Therapeutics Inc
Profile last edited on: 4/23/18      CAGE:       UEI:

Business Identifier: Anti-viral drug developmen
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3401 Market Street Suite 300 Un Sci Ctr
Philadelphia, PA 19104
   (215) 386-5220
Location: Single
Congr. District: 03
County: Philadelphia

Public Profile

In July 1997 Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) acquired Avid Corporation. This acquisition will provide Triangle access to a novel protease inhibitor to complement its portfolio of anti-HIV compounds. Triangle was itself subsequently acquired by Gilead (NASDAQ: GILD), itself having been an SBIR-involved firm.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1998 1 NIH $100,000
Project Title: New Treatment Strategies for Hepatitis C
1993 1 NIH $49,410
Project Title: Hepatitus B virus polymerase as an antiviral drug target

Key People / Management

  Forrest H Anthony -- President

  Christopher S Barker

  Curt H Hagedorn

Company News

There are no news available.